| Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Male and Female Acne: Phase 3 Analysis.J Drugs Dermatol | PMID 39361705无 PMCID | 2024-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer.JAMA Netw Open | PMID 39374015PMC11581504 | 2024-Oct-01 | 0.90 | The record describes a biomarker prognostic analysis from a Phase III randomized trial. While the parent trial likely had a drug intervention, this specific report focuses on the prognostic value of circulating tumor cell count. It does not present the primary efficacy results of a drug-containing intervention compared to another. Therefore, it is excluded as a secondary/biomarker analysis. | 待处理 |
| Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical Trial.JAMA Netw Open | PMID 39405060PMC11581638 | 2024-Oct-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Morphomics, Survival, and Metabolites in Patients With Metastatic Pancreatic Cancer.JAMA Netw Open | PMID 39418020PMC11581562 | 2024-Oct-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Exploring the feasibility, acceptability and preliminary effects of a nurse delivered mhealth intervention for women living with HIV in South India: a pilot randomized controlled trial.Arch Womens Ment Health | PMID 38630259无 PMCID | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and Efficacy of CLS-TA by Anatomic Location of Inflammation: Results from the Phase 3 PEACHTREE Clinical Trial.Ocul Immunol Inflamm | PMID 38194432无 PMCID | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The Effect of Nabiximols on Driving Ability in Adults with Chronic Tic Disorders: Results of a Substudy Analysis of the Double-Blind, Randomized, Placebo-Controlled CANNA-TICS Trial.Cannabis Cannabinoid Res | PMID 38265476无 PMCID | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of Once-Daily Vilanterol/Fluticasone furoate MDI in persistent asthma: Phase 3 OD-INHALE Study.J Asthma | PMID 38488853无 PMCID | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure.Clin Gastroenterol Hepatol | PMID 38492904无 PMCID | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide.Eur Urol Oncol | PMID 38523017PMC12037053 | 2024-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of oral ibrexafungerp in Chinese patients with vulvovaginal candidiasis: a phase III, randomized, double-blind study.Infection | PMID 38568411PMC11499449 | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study.Eur Urol | PMID 38644146无 PMCID | 2024-Oct | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Multivariate Cluster Analyses to Characterize Asthma Heterogeneity and Benralizumab Responsiveness.J Allergy Clin Immunol Pract | PMID 38663470无 PMCID | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Correlation Between Blue Fundus Autofluorescence and SD-OCT Measurements of Geographic Atrophy in Dry Age-Related Macular Degeneration.Am J Ophthalmol | PMID 38719131无 PMCID | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies.Clin Gastroenterol Hepatol | PMID 38723981无 PMCID | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC.J Thorac Oncol | PMID 38729426无 PMCID | 2024-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial.J Hepatol | PMID 38734383无 PMCID | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 study.Allergol Int | PMID 38735810无 PMCID | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis.J Eur Acad Dermatol Venereol | PMID 38785405无 PMCID | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY).Gastroenterology | PMID 38788861无 PMCID | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study.Clin Lymphoma Myeloma Leuk | PMID 38849283无 PMCID | 2024-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE.Ann Hematol | PMID 38888616PMC11512864 | 2024-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Prognostic value of lymphocytes in patients with breast cancer receiving radiotherapy after breast-conserving surgery: A post hoc analysis of a phase III randomized trial.Radiother Oncol | PMID 38897316无 PMCID | 2024-Oct | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Impact of relugolix combination therapy on functioning and quality of life in women with endometriosis-associated pain.Fertil Steril | PMID 38906210无 PMCID | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sex- and age-related shift of relapse phenotypes in a cohort of relapsing multiple sclerosis patients: Post hoc analysis from the OPERA phase 3 trials.Eur J Neurol | PMID 38925580PMC11414797 | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Hydroxyurea to prevent brain injury in children with sickle cell disease (HU Prevent)-A randomized, placebo-controlled phase II feasibility/pilot study.Am J Hematol | PMID 38953438PMC11502276 | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial.Lancet Infect Dis | PMID 38964361无 PMCID | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial.Ann Oncol | PMID 38964714无 PMCID | 2024-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial.Ann Oncol | PMID 38986769无 PMCID | 2024-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A phase 3, randomized, double-blind, multicenter, placebo-controlled study of S-588410, a five-peptide cancer vaccine as an adjuvant therapy after curative resection in patients with esophageal squamous cell carcinoma.Esophagus | PMID 38990441PMC11405444 | 2024-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial.Nat Med | PMID 38992123PMC11485241 | 2024-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effective treatment of actinic keratosis on the hands with red light photodynamic therapy using BF-200 ALA.Photodiagnosis Photodyn Ther | PMID 39002836无 PMCID | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations.Int J Clin Oncol | PMID 39017806PMC11420312 | 2024-Oct | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Network intervention analysis indicates that roluperidone achieves its effect on negative symptoms of schizophrenia by targeting avolition.Eur Neuropsychopharmacol | PMID 39024856无 PMCID | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Trivalent chromium versus baricitinib for rheumatoid arthritis treatment: first phase 2/3 randomized controlled trial, is trivalent chromium the upcoming immune-modulator?Inflammopharmacology | PMID 39030450PMC11416422 | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.Gynecol Oncol | PMID 39032397无 PMCID | 2024-Oct | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Long-term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52-week extension of a Phase 3 randomized controlled trial.Diabetes Obes Metab | PMID 39054871无 PMCID | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery.Qual Life Res | PMID 39066879PMC11577575 | 2024-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial.Lancet Haematol | PMID 39067465无 PMCID | 2024-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast Cancer.Clin Breast Cancer | PMID 39069436无 PMCID | 2024-Oct | 0.95 | The record describes a Phase III, randomized, double-blind clinical trial in human oncology (HER2-positive metastatic breast cancer) with a drug intervention (ZRC-3277, a pertuzumab biosimilar). It is an original result report. However, the primary efficacy endpoint is objective response rate (ORR), and no time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) is reported or designated as a primary or key secondary objective. Therefore, it does not meet the cohort's requirement for a primary/key secondary time-to-event efficacy endpoint. | 待处理 |
| Ultra-low-dose estradiol and dydrogesterone for treatment of vasomotor symptoms in Europe and China.Climacteric | PMID 39077780无 PMCID | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Characteristics and outcome of synchronous bilateral Wilms tumour in the SIOP WT 2001 Study: Report from the SIOP Renal Tumour Study Group (SIOP-RTSG).Br J Cancer | PMID 39080350PMC11405756 | 2024-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Daridorexant in Japanese patients with insomnia disorder: A phase 3, randomized, double-blind, placebo-controlled study.Sleep Med | PMID 39116704无 PMCID | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinical trial: Effects of treatment with a vibrating capsule in patients with severe chronic constipation.Aliment Pharmacol Ther | PMID 39126191无 PMCID | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| BCG vaccination of healthcare workers for protection against COVID-19: 12-month outcomes from an international randomised controlled trial.J Infect | PMID 39127450PMC11409612 | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Integrated analysis of older adults and patients with renal dysfunction in the IMpower130 and IMpower132 randomized controlled trials for advanced non-squamous non-small cell lung cancer.Lung Cancer | PMID 39127586无 PMCID | 2024-Oct | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Long-term safety and efficacy of daridorexant in Japanese patients with insomnia disorder.Sleep Med | PMID 39128336无 PMCID | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform.J Neurol | PMID 39138650PMC11447117 | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial.Lancet Respir Med | PMID 39146944无 PMCID | 2024-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Tapinarof cream for the treatment of plaque psoriasis: Efficacy and safety results from 2 Japanese phase 3 trials.J Dermatol | PMID 39150292PMC11484133 | 2024-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |